case_images: PMC10850310_01
case_images: Toxic epidermal necrolysis. (A-C). HD#7: Prior to the first etanercept injection, the patient had maculopapular rashes and vesicles throughout the body. (D-F). HD#11: After the first dose of etanercept, epithelization began, but some vesicles and bullae remained. (G-I). HD#18: After the second dose of etanercept, the patient's skin was mostly epithelialized. HD, hospital day.
case_images: fimmu-15-1342898-g001.jpg
case_images: PMC10850310_01_fimmu-15-1342898-g001.jpg
case_images: f1
case_images: TEN (SCORTEN) of 1 (tachycardia, heart rate 162), deflazacort was discontinued, and dexamethasone (1.5 mg/kg/day), a 5-day course of IVIG (0.4 mg/kg/day), and cyclosporine 3 mg/kg/day were initiated. The lesions appeared to be stationary for 3 days; however, when IVIG was discontinued on the 6th day of hospitalization, the vesicular lesions progressed to approximately 60% of BSA ( Figures 1A-C ). However, when re-evaluated on day 15, approximately 30% of the BSA was still involved ( Figures 1D-F ); therefore, a second dose of 0.8 mg/kg of etanercept was administered. Since then, the patient's condition improved without any complications ( Figure 1G-I ).
case_images: Skin detachment extent according to time. Extent of skin detachment due to toxic epidermal necrolysis during admission. Etanercept (0.8 mg/kg) was injected on hospital day #7 and hospital day #14. BSA, body surface area; HD, hospital day.
case_images: fimmu-15-1342898-g002.jpg
case_images: PMC10850310_01_fimmu-15-1342898-g002.jpg
case_images: f2
case_images: Etanercept (0.8 mg/kg) was administered subcutaneously ( Figure 2 ).